Seaport reported positive topline data from a Phase 1 driving simulation trial of GlyphAllo and dosed the first patient in a Phase 2a trial of GlyphAgo, with cash runway expected to fund operations into 2029.
Seaport reported positive topline data from a Phase 1 driving simulation trial of GlyphAllo and dosed the first patient in a Phase 2a trial of GlyphAgo, with cash runway expected to fund operations into 2029.